Contrasting Aquinox Pharmaceuticals (NASDAQ:AQXP) & Regeneron Pharmaceuticals (NASDAQ:REGN)

Aquinox Pharmaceuticals (NASDAQ:AQXP) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation and dividends.

Analyst Recommendations

This is a summary of recent ratings and price targets for Aquinox Pharmaceuticals and Regeneron Pharmaceuticals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aquinox Pharmaceuticals 0 0 0 0 N/A
Regeneron Pharmaceuticals 1 13 4 1 2.26

Regeneron Pharmaceuticals has a consensus price target of $389.81, indicating a potential upside of 30.65%. Given Regeneron Pharmaceuticals’ higher possible upside, analysts plainly believe Regeneron Pharmaceuticals is more favorable than Aquinox Pharmaceuticals.

Insider and Institutional Ownership

71.7% of Aquinox Pharmaceuticals shares are held by institutional investors. Comparatively, 66.9% of Regeneron Pharmaceuticals shares are held by institutional investors. 4.0% of Aquinox Pharmaceuticals shares are held by company insiders. Comparatively, 11.8% of Regeneron Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Volatility and Risk

Aquinox Pharmaceuticals has a beta of -7.22, indicating that its stock price is 822% less volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 1.11, indicating that its stock price is 11% more volatile than the S&P 500.

Earnings and Valuation

This table compares Aquinox Pharmaceuticals and Regeneron Pharmaceuticals’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Aquinox Pharmaceuticals $25.00 million 2.36 -$31.58 million N/A N/A
Regeneron Pharmaceuticals $6.71 billion 4.86 $2.44 billion $19.80 15.07

Regeneron Pharmaceuticals has higher revenue and earnings than Aquinox Pharmaceuticals.

Profitability

This table compares Aquinox Pharmaceuticals and Regeneron Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Aquinox Pharmaceuticals N/A -24.61% -22.21%
Regeneron Pharmaceuticals 35.13% 26.95% 19.76%

Summary

Regeneron Pharmaceuticals beats Aquinox Pharmaceuticals on 11 of the 12 factors compared between the two stocks.

About Aquinox Pharmaceuticals

Aquinox Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in developing novel therapeutics for chronic urological conditions by inflammation and pain. The company focuses on a library of novel compounds that activate SH2-containing inositol-5'-phosphatase 1 (SHIP1) to develop therapeutics for application in inflammation, inflammatory pain, and blood cancers. Its lead product candidate is Rosiptor (Leadership 301), a small molecule activator of SHIP1 that is in Phase III clinical trials for treatment in interstitial cystitis/bladder pain syndrome. The company was formerly known as Aquinox Pharmaceuticals (USA) Inc. and changed its name to Aquinox Pharmaceuticals, Inc. in January 2014. Aquinox Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma in adults and adolescents; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it is developing various product candidates for treating patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases, and other diseases. The company has collaboration and license agreements with Sanofi, Bayer, Teva, Mitsubishi Tanabe Pharma, Alnylam Pharmaceuticals, Inc., and others. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.

Receive News & Ratings for Aquinox Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.